Evidence map›Paper›PMID 26757811›Full record

ArticleBioTechniques2016

A simple, low-cost staining method for rapid-throughput analysis of tumor spheroids.

Frank Eckerdt, Angel Alvarez, Jonathan Bell, Constadina Arvanitis, Asneha Iqbal, Ahmet D Arslan, Bo Hu, Shi-Yuan Cheng, Stewart Goldman, Leonidas C Platanias

Abstract read
In one paragraph

Article in BioTechniques, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Frank EckerdtRobert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Angel AlvarezDepartment of Neurology, Robert H. Lurie Comprehensive Cancer Center, Northwestern Brain Tumor Institute, Northwestern University Feinberg School of Medicine, Chicago, IL.
Jonathan BellRobert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Constadina ArvanitisCenter for Advanced Microscopy and Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Asneha IqbalRobert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Ahmet D ArslanRobert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Bo HuDepartment of Neurology, Robert H. Lurie Comprehensive Cancer Center, Northwestern Brain Tumor Institute, Northwestern University Feinberg School of Medicine, Chicago, IL.
Shi-Yuan ChengDepartment of Neurology, Robert H. Lurie Comprehensive Cancer Center, Northwestern Brain Tumor Institute, Northwestern University Feinberg School of Medicine, Chicago, IL.
Stewart GoldmanRobert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Leonidas C PlataniasRobert H. Lurie Comprehensive Cancer Center and Division of Hematology-Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL.

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008152 · NIGMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ARDEHALI, HOSSEIN · 1987 to 2021
$24.0M
CARCINOGENESIS TRAINING PROGRAMT32CA009560 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Kathleen Janee Green · 1986 to 2026
$8.4M
Signal Transduction of Type I Interferons in Malignant CellsR01CA077816 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 1998 to 2024
$6.6M
TRAINING PROGRAM IN SIGNAL TRANSDUCTION AND CANCERT32CA070085 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1997 to 2026
$5.7M
Targeting Novel Protein Complexes for the Treatment of Acute Myeloid LeukemiaR01CA121192 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 2006 to 2023
$4.1M
Cohort and biomarkers for COVID-19 severity, natural history, and reinfectionR01AI158911 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI BARRETT, EMILY S, BLASER, MARTIN J · 2021 to 2023
$2.6M
Glioblastoma Phenotype Modulation Through miRNA Control of Wnt SignalingR01NS093843 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CHENG, SHI-YUAN · 2015 to 2019
$1.8M
Modulation of Oncogenic Signaling in GlioblastomasR01CA159811 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CHENG, SHI-YUAN · 2012 to 2016
$1.8M
Autophagy Regulation of Glioblastoma Tumorigenesis and Responses to TherapyR01NS095634 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI CHENG, SHI-YUAN · 2015 to 2019
$1.7M
Mnk Pathways and IFN-responses in Malignant CellsR01CA155566 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI PLATANIAS, LEONIDAS C. · 2011 to 2015
$1.6M
Signaling Pathways and Therapeutic Targeting of Leukemic CellsI01CX000916 · VA · JESSE BROWN VA MEDICAL CENTER · PI PLATANIAS, LEONIDAS C. · 2013 to 2025
–
CSRD VA I01 CX000916NCI NIH HHS CA060553NCI NIH HHS CA155566NCI NIH HHS CA77816NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA077816NCI NIH HHS R01 CA121192NCI NIH HHS R01 CA155566NCI NIH HHS R01 CA158911NCI NIH HHS R01 CA158911-S3NCI NIH HHS R01 CA159811NCI NIH HHS T32 CA009560NCI NIH HHS T32 CA070085NCI NIH HHS T32 CA09560NIAID NIH HHS R01 AI158911NIGMS NIH HHS T32 GM008152NINDS NIH HHS R01 NS093843NINDS NIH HHS R01 NS095634
6 · The paper itself

Abstract

Tumor spheroids are becoming an important tool for the investigation of cancer stem cell (CSC) function in tumors; thus, low-cost and high-throughput methods for drug screening of tumor spheroids are needed. Using neurospheres as non-adherent three-dimensional (3-D) cultures, we developed a simple, low-cost acridine orange (AO)-based method that allows for rapid analysis of live neurospheres by fluorescence microscopy in a 96-well format. This assay measures the cross-section area of a spheroid, which corresponds to cell viability. Our novel method allows rapid screening of a panel of anti-proliferative drugs to assess inhibitory effects on the growth of cancer stem cells in 3-D cultures.

Indexed as

Acridine OrangeBiological AssayBrain NeoplasmsCell Line, TumorCell ProliferationCell SurvivalGlioblastomaHumansNeoplastic Stem CellsSpheroids, CellularStaining and LabelingAcridine Orangeacridine orangecancer stem cellglioblastomamicroscopyneurospherestumor spheroids

Identifiers

PMID26757811
PMCPMC4772731

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.